PREVENTION AND TREATMENT OF THROMBOSIS IN MEDICALLY ILL PATIENTS
Provided herein are methods for preventing and treating thrombosis in medically ill patients by administering to the patient a therapeutically effective amount of betrixaban.
1 . A method for the prevention or treatment of thrombosis in an acute medically ill patient at risk of developing venous thromboembolism (VTE), comprising administering to the patient a therapeutically effective amount of betrixaban.
2 . The method of claim 1 , wherein the patient suffers from decreased mobility.
3 . The method of claim 2 , wherein the decreased mobility arises from one or more of (a) acutely decompensated heart failure, (b) acute respiratory failure, (c) acute infection without septic shock, (d) an acute rheumatic disorder or (e) cancer.
4 . (canceled)
5 . The method of claim 2 , wherein betrixaban is administered to the patient once daily.
6 . The method of claim 2 , wherein betrixaban is in the form of a pharmaceutically acceptable salt.
7 . The method of claim 6 , wherein the pharmaceutically acceptable salt of betrixaban is a maleate salt.
8 . The method of claim 5 , wherein betrixaban is administered in an amount of about 20 mg to about 80 mg per day.
9 . The method of claim 5 , wherein betrixaban is administered in an amount of about 40 mg to about 80 mg per day.
10 . The method of claim 1 , wherein betrixaban is administered with food.
11 . The method of claim 1 , wherein the patient receives about 160 mg of betrixaban prior to the administration.
12 . (canceled)
13 . The method of claim 9 , wherein the administration continues for at least 35 days.
14 . The method of claim 9 , wherein the patient is at risk of major or clinically relevant bleeding.
15 . The method of claim 9 , wherein the patient suffers from kidney insufficiency.
16 . A method for the prevention or treatment of thrombosis in an acute medically ill patient suffering from decreased mobility and at risk of developing venous thromboembolism (VTE), comprising administering to the patient a therapeutically effective amount of betrixaban from 40 mg to 80 mg daily for at least 35 days.
17 . The method of claim 16 , wherein the patient is at risk of major or clinically relevant bleeding.
18 . The method of claim 16 , wherein the patient suffers from kidney insufficiency.